voxilaprevir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Hepatitis Virus C (HVC) protease inhibitors 5242 1535212-07-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • voxilaprevir
  • GS-9857
Voxilaprevir is a noncovalent, reversible inhibitor of the NS3/4A protease, which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical inhibition assay, voxilaprevir inhibited the proteolytic activity of recombinant NS3/4A enzymes from clinical isolates of HCV genotypes 1b and 3a with Ki values of 38 and 66 pM, respectively.
  • Molecular weight: 868.94
  • Formula: C40H52F4N6O9S
  • CLOGP: 6.69
  • LIPINSKI: 3
  • HAC: 15
  • HDO: 3
  • TPSA: 195.22
  • ALOGS: -4.23
  • ROTB: 8

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 18, 2017 FDA GILEAD SCIENCES INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fatigue 65.32 51.25 40 217 608657 46077148
Headache 52.32 51.25 32 225 478320 46207485

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatitis C 269.64 61.09 63 700 13142 29938573
Treatment failure 213.68 61.09 64 699 34615 29917100
Fatigue 164.48 61.09 100 663 320573 29631142
Headache 84.77 61.09 54 709 182252 29769463
Hepatocellular carcinoma 77.52 61.09 22 741 9588 29942127
Drug ineffective 66.52 61.09 60 703 340327 29611388

Pharmacologic Action:

SourceCodeDescription
ATC J05AP56 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000182638 HCV NS3/4A Protease Inhibitors
FDA EPC N0000182639 Hepatitis C Virus NS3/4A Protease Inhibitor
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190107 Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA N0000190108 Organic Anion Transporting Polypeptide 1B3 Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.64 acidic
pKa2 1.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
400MG;100MG;100MG VOSEVI GILEAD SCIENCES INC N209195 July 18, 2017 RX TABLET ORAL July 18, 2022 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Genome polyprotein Polyprotein INHIBITOR Ki 10.42 DRUG LABEL DRUG LABEL
Genome polyprotein Polyprotein INHIBITOR Ki 10.18 DRUG LABEL DRUG LABEL

External reference:

IDSource
4036863 VANDF
C4507237 UMLSCUI
L9P PDB_CHEM_ID
CHEMBL3707372 ChEMBL_ID
D10899 KEGG_DRUG
C000619503 MESH_SUPPLEMENTAL_RECORD_UI
10143 INN_ID
0570F37359 UNII
89921642 PUBCHEM_CID
DB12026 DRUGBANK_ID
1939323 RXNORM
32914 MMSL
d08618 MMSL
017285 NDDF
736536005 SNOMEDCT_US
816106001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vosevi HUMAN PRESCRIPTION DRUG LABEL 3 61958-2401 TABLET, FILM COATED 100 mg ORAL NDA 34 sections